India’s Jubilant Organosys group has announced that Clinsys Clinical Research, its US-based contract research organisation (CRO), has acquired TrialStat ClinicalAnalytics (TrialStat CA), a web-based electronic data capture (EDC) solution, from Canada’s TrialStat Corporation for Can$750,000 (US$608,569).

According to Jubilant, TrialStat CA is the first EDC platform that allows all aspects of a clinical trial to be configured, deployed and managed through a browser interface, enabling customers to start their studies quickly and cost-effectively. The company “had identified TrialStat ClinicalAnalytics as one of the most innovative EDC solutions on the market and was determined to include it in its offerings to its customers globally”, Jubilant noted.

Clinsys’ “extensive global resources” will give TrialStat’s existing CRO and biopharmaceutical customer base a broader scope of services, it said. Meanwhile, the addition of TrialStat CA to Clinsys’ portfolio will allow the CRO to “continue to expand its integrated solutions for pharmaceutical, biotechnology and medical device organisations,” commented Shyam Bhartia and Hari Bhartia, respectively chairman and managing director and co-chairman and managing director of Jubilant Organosys.

“The acquisition is an excellent fit and addresses the industry’s continuously evolving requirements in EDC,” they added.

Headquartered in Bedminster, New Jersey, Clinsys Clinical Research offers a range of Phase I-IV services including clinical development, study start-up, clinical operations, biostatistics, data management, quality assurance, regulatory affairs, pharmacovigilance, medical writing, clinical pharmacology and pathology, and functional outsourcing.